Abstract: A delivery device for zero-order release of an active principle into a dissolution fluid includes a reservoir consisting of a solid matrix of a homogeneous mixture of a polymer material, at least a portion of the active principle and an additive soluble in the dissolution fluid with negative heat of solution, a coating on the solid matrix-type reservoir of a first, release rate-controlling insoluble membrane which modulates the active principle release according to the desired kinetics; and a second, protective membrane on the release rate-controlling membrane of a soluble polymer material.

Abstract: The water soluble derivatives of cephalexin, having general formula: ##STR1## wherein X represents an alkali metal or the organic nitrogen containing cation of a basic aminoacid, combine the typical antibiotic action of cephalexin with the water solubility and form essentially neutral, aqueous solutions. The process for the preparation of the above derivatives comprises a first step in which the methylol derivative of cephalexin is prepared and a second step in which the treatment with a suitable base is carried out.

Abstract: The esters of pyridoxine and of isopropylidene pyridoxine with 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-indol-3-acetic acid and 5-(2,4-difluorophenyl)-salicylic acid are essentially endowed with the same activities of the corresponding acids and are less toxic and gastrolesive, whereby the therapeutical index is remarkably improved. For the preparation of these compounds the chloride of the acid is reacted with isopropylidene pyridoxine, followed by a hydrolysis to obtain the corresponding pyridoxine derivative.

Abstract: The nicotinic ester of (3-4)-O-isopropylidene pyridixole having the formula: ##STR1## shows analgesic and anti-inflammatory activity.

Abstract: The invention relates to esters of 3-hydroxy-quinuclidine with phenoxycarboxylic acids, and their salts having general formula: ##STR1## wherein R.sub.1 represents H,CH.sub.3, and R.sub.2 represents H, Cl,Br or a radical of an acid of the group comprising oleic, pivalic, nicotinic, clofibric, pyridineacetic and teophyllineacetic acid.The compounds of the invention jointly show hypocholesteremizing and hypotriglyceridimizing activity, combined with other therapeutically interesting properties, such as beta-blocking, diuretic, anti-inflammatory activity.The invention furthermore relates to the pharmaceutical compositions containing the compounds of the invention as the active ingredients.

Abstract: The amide derivatives of p-isobutyl-phenyl-propionic acid, having general formula ##STR1## wherein X is the radical of a substituted amine, of the group comprising lysine, metatrifluorotoluidine, glutamic acid and aspartic acid, show a good anti-inflammatory activity, accompanied by favourable side properties. For the preparation of the compounds of the invention, the p-isobutyl-phenyl-propionic acid is chlorinated, and the chlorinated derivative is reacted with the proper substituted amine.

Abstract: Esters of salicylamide with anti-inflammatory and analgesic action are disclosed.These esters have the following general formula: ##STR1## wherein R is a radical of an acid selected among d-2-(6'-methoxy-2'-naphtyl)-propionic acid, 2[[3-(trifluoromethyl)phenyl]-amino]-3-pyridine carboxylic acid, 2- {[3-(trifluoromethyl)-phenyl]-amino}-3-pyridincarboxylic acid, 2-(4-isobutyl-phenyl)-propionic acid, 4-allyloxy-3-chloro-phenylacetic acid, 2-(3-benzoylphenyl)-propionic acid, 2-[(2,3-dimethylphenyl)amino]-benzoic acid and 2[[3-trifluoromethyl)phenyl]-amino]benzoic acid.The process for preparing the subject esters comprises reacting a halide, preferably a chloride of the desired acid, with a solution of salicylamide.

Abstract: The invention concerns novel piridoxine derivatives of the general formula: ##STR1## which show anti-inflammatory activity and moreover may show, although not necessarily, also analgesic and/or anti-pyretic activity.

Abstract: The invention concerns novel piridoxine derivatives of the general formula: ##STR1## which show anti-inflammatory activity and moreover may show, although not necessarily, also analgesic and/or anti-pyretic activity.

Abstract: For the treatment of cardiac hypertrophy, d-glucosamine salts of the 3',5'-adenosine monophosphoric cyclic acid (AMP-c) and of the dibutyl ester thereof are disclosed, these salts having a reduced acute toxicity and an improved activity on the mitochondria of hypertrophic heart with respect to the cyclic AMP acid alone or its dibutyl ester. The compounds in question are useful for the treatment of cardiac hypertrophy and alteration of the energetic muscular metabolism.